◀ Anchor ▶
A domestic pharmaceutical company’s COVID-19 treatment was approved for use, and a’recommendation’ was issued for the AstraZeneca vaccine introduced overseas.
However, it will take a little longer for large-scale use as additional data submission or discussion is required.
Reporter Jeon Jeon Hyuk reports.
◀ Report ▶
The Korean pharmaceutical company Celltrion has approved the domestic use of the Corona 19 antibody treatment’Rekirona’.
The Ministry of Food and Drug Safety announced that it had decided that there was no problem as a result of reviewing the safety and effectiveness by holding a meeting of the final inspection committee for’Recyronaju’ today.
The targets of the’rekironazu’ antibody therapy are those who are 60 years of age or older,’high-risk’ mild patients with one or more of cardiovascular disease, chronic respiratory disease, diabetes, and high blood pressure, and patients with moderate illness.
A’moderately ill patient’ is a patient with clinical symptoms of pneumonia or an imaging observation of pneumonia, but patients with severe pneumonia are excluded from administration.
==============================
A recommendation for permission was issued for the Corona 19 vaccine developed by AstraZeneca.
The Ministry of Food and Drug Safety’s Central Pharmacy Review Committee recommends permission to use the AstraZeneca vaccine for those aged 18 or older, but stated that the administration of the vaccine for the aged 65 years or older should be further discussed at the Korea Centers for Disease Control and Prevention. It.
Earlier, he explained that some countries, such as Germany and France, require additional analysis to verify the effectiveness, such as restricting vaccinations to the elderly.
Accordingly, the domestic use of AstraZeneca vaccine will be finalized after further discussions by the Korea Disease Administration and the final inspection committee meeting of the Ministry of Food and Drug Safety.
This is MBC News.
MBC News awaits your report 24 hours a day.
▷ Phone 02-784-4000
▷ Email [email protected]
▷ KakaoTalk @mbc report